Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06653322 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Enrollment target: estimated 400 to confirmed 401 · Site details revisedv4 Show 2 more changesShow less
    • Enrollment target: estimated 400 to confirmed 401
    • Site details revised
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 360 to 400 · Start date changed from estimate of Oct 2024 to Nov 21, 2024 · Secondary endpoints: 17 to 16 · 1 morev2 Show 4 more changesShow less
    • Enrollment target: 360 to 400
    • Start date changed from estimate of Oct 2024 to Nov 21, 2024
    • Secondary endpoints: 17 to 16
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype
Trial Details
NCT Number NCT06653322
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Asthma With Eosinophilic Phenotype
Enrollment 401 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov